Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target at $826.59

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $826.5909.

Several equities research analysts have issued reports on REGN shares. Truist Financial dropped their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a report on Thursday, April 30th. Royal Bank Of Canada dropped their price objective on Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a report on Thursday, April 30th. Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $825.00 to $800.00 and set an “equal weight” rating on the stock in a report on Thursday, April 30th. Piper Sandler started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 target price for the company. Finally, Guggenheim lifted their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research report on Friday, May 1st.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. The trade was a 49.03% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,874 shares of company stock worth $3,013,262. 6.97% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Insigneo Advisory Services LLC grew its position in shares of Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after acquiring an additional 13 shares in the last quarter. Arjuna Capital grew its position in shares of Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares in the last quarter. Guardian Wealth Advisors LLC NC grew its position in shares of Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares in the last quarter. TD Private Client Wealth LLC boosted its position in Regeneron Pharmaceuticals by 9.7% during the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the period. Finally, MCF Advisors LLC boosted its position in Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $714.89 on Friday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The stock’s 50 day moving average is $752.68 and its two-hundred day moving average is $740.44. The company has a market capitalization of $75.58 billion, a PE ratio of 17.42, a P/E/G ratio of 1.60 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the previous year, the business earned $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals will post 37.08 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th will be given a $0.94 dividend. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.